bispecific antibody bnt142 Search Results


bispecific antibody bnt142  (BioNTech)
90
BioNTech bispecific antibody bnt142
Summary of on-going clinical studies of mRNA vaccines for cancer.
Bispecific Antibody Bnt142, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bispecific+antibody+bnt142/pmc10758055-77-7-20?v=BioNTech
Average 90 stars, based on 1 article reviews
bispecific antibody bnt142 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
t-cell-engaging bispecific antibody against cldn6 and the t-cell receptor–associated molecule cd3  (BioNTech)
90
BioNTech t-cell-engaging bispecific antibody against cldn6 and the t-cell receptor–associated molecule cd3
Representative completed and ongoing clinical studies (immunotherapy)
T Cell Engaging Bispecific Antibody Against Cldn6 And The T Cell Receptor–Associated Molecule Cd3, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bispecific+antibody+bnt142/pmc11564800-32-17-36?v=BioNTech
Average 90 stars, based on 1 article reviews
t-cell-engaging bispecific antibody against cldn6 and the t-cell receptor–associated molecule cd3 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Summary of on-going clinical studies of mRNA vaccines for cancer.

Journal: Theranostics

Article Title: Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape

doi: 10.7150/thno.84291

Figure Lengend Snippet: Summary of on-going clinical studies of mRNA vaccines for cancer.

Article Snippet: BNT142 , bispecific antibody, against CLDN6 and CD3 , Solid Tumor , i.v. , NCT05262530 , I/II , Recruiting , BioNTech , LNP.

Techniques: Vaccines, Immunopeptidomics

Representative completed and ongoing clinical studies (immunotherapy)

Journal: Signal Transduction and Targeted Therapy

Article Title: Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

doi: 10.1038/s41392-024-02002-z

Figure Lengend Snippet: Representative completed and ongoing clinical studies (immunotherapy)

Article Snippet: , , BNT142 , CLDN6-positive solid tumors , T-cell-engaging bispecific antibody against CLDN6 and the T-cell receptor–associated molecule CD3 , LNPs , Intravenous bolus/infusion , 2022-03-28 , Phase I/II , Recruiting , / , NCT05262530 , BioNTech SE , .

Techniques: Virus, Injection, Membrane, Adjuvant, Activity Assay, Plasmid Preparation, Saline, Electroporation, Transfection, Inhibition